Having trouble accessing articles? Reset your cache.

Roller-coaster ride for Sarepta after ‘erroneous’ adverse event report

Sarepta found itself needing to set the record straight Thursday after an adverse event report for its DMD gene therapy sent shares down by as much as $27.26 (19%) to $115.

According to the report filed with

Read the full 364 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers